Leadership

Jean-Pierre Kinet

Dr. Kinet is currently Professor of Pathology at Harvard Medical School and the Director of the Division of Allergy and Immunology at the Beth Israel Deaconess Medical Center. He is a Director and member of the Scientific Committee of UCB, Scientific Founder of Astarix (acquired by Heska), and Director of Qualyst, in addition to other board memberships. Previously he served as the Head of the Molecular Allergy and Immunology section of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Kinet has authored over 170 publications, holds 10 issued patents, and is renowned for his cloning of the high-affinity IgE receptor. He is a former practicing physician and earned his medical degree (M.D.) from the University of Liège.

Albert Hsia

Prior to joining iXLife, Dr. Hsia was Head of Business Development at Synta Pharmaceuticals, where he led the negotiation and management of alliances totaling over $1 billion in potential value. He also played central roles in acquisitions, private placements, and public offerings, and he held management roles in early research and development. Prior to joining Synta, Dr. Hsia was a research fellow at the CNRS Institute of Biological Sciences. He received his Ph.D. in neuroscience at U.C. San Francisco and his B.A. in chemistry and physics at Harvard University.

Marina Iche

Prior to joining iXLife, Ms. Iche was Head of Clinical Operations, Regulatory Affairs, and Quality Assurance at AB Science where she led the execution by an international team of numerous early- and late-stage clinical trials. Prior to joining AB Science, she held various operational roles in large pharmaceutical companies, CROs, and consulting organizations, including as International Clinical Project Manager for Aventis and Pharmacia, and as International Clinical Project Manager and Quality Assurance Auditor for Pfizer. She is a graduate of the University of Pharmacy of Montpellier.